429 related articles for article (PubMed ID: 23374281)
1. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
3. Heparanase regulates levels of syndecan-1 in the nucleus.
Chen L; Sanderson RD
PLoS One; 2009; 4(3):e4947. PubMed ID: 19305494
[TBL] [Abstract][Full Text] [Related]
4. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
Sanderson RD; Elkin M; Rapraeger AC; Ilan N; Vlodavsky I
FEBS J; 2017 Jan; 284(1):42-55. PubMed ID: 27758044
[TBL] [Abstract][Full Text] [Related]
5. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
[TBL] [Abstract][Full Text] [Related]
6. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes.
Thompson CA; Purushothaman A; Ramani VC; Vlodavsky I; Sanderson RD
J Biol Chem; 2013 Apr; 288(14):10093-10099. PubMed ID: 23430739
[TBL] [Abstract][Full Text] [Related]
7. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
[TBL] [Abstract][Full Text] [Related]
8. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.
Purushothaman A; Hurst DR; Pisano C; Mizumoto S; Sugahara K; Sanderson RD
J Biol Chem; 2011 Sep; 286(35):30377-30383. PubMed ID: 21757697
[TBL] [Abstract][Full Text] [Related]
9. Targeting heparanase for cancer therapy at the tumor-matrix interface.
Sanderson RD; Iozzo RV
Matrix Biol; 2012 Jun; 31(5):283-4. PubMed ID: 22655968
[No Abstract] [Full Text] [Related]
10. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
[TBL] [Abstract][Full Text] [Related]
11. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
12. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
13. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
14. Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression.
Rangarajan S; Richter JR; Richter RP; Bandari SK; Tripathi K; Vlodavsky I; Sanderson RD
J Histochem Cytochem; 2020 Dec; 68(12):823-840. PubMed ID: 32623935
[TBL] [Abstract][Full Text] [Related]
15. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells.
Masola V; Gambaro G; Tibaldi E; Onisto M; Abaterusso C; Lupo A
Biochim Biophys Acta; 2011 Aug; 1813(8):1475-82. PubMed ID: 21600934
[TBL] [Abstract][Full Text] [Related]
16. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.
Ramani VC; Yang Y; Ren Y; Nan L; Sanderson RD
J Biol Chem; 2011 Feb; 286(8):6490-9. PubMed ID: 21131364
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation.
Teixeira FCOB; Götte M
Adv Exp Med Biol; 2020; 1221():97-135. PubMed ID: 32274708
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate mediates trastuzumab effect in breast cancer cells.
Suarez ER; Paredes-Gamero EJ; Del Giglio A; Tersariol IL; Nader HB; Pinhal MA
BMC Cancer; 2013 Oct; 13():444. PubMed ID: 24083474
[TBL] [Abstract][Full Text] [Related]
19. Heparanase activates the syndecan-syntenin-ALIX exosome pathway.
Roucourt B; Meeussen S; Bao J; Zimmermann P; David G
Cell Res; 2015 Apr; 25(4):412-28. PubMed ID: 25732677
[TBL] [Abstract][Full Text] [Related]
20. Heparanase-Regulated Syndecan-1 Shedding Facilitates Herpes Simplex Virus 1 Egress.
Hadigal S; Koganti R; Yadavalli T; Agelidis A; Suryawanshi R; Shukla D
J Virol; 2020 Feb; 94(6):. PubMed ID: 31827001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
